Patient
SITE003-0130
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE003 (CAN) (Dr. Okafor)
consented 2026-02-05
Adverse events
3
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 3
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-22 (study day 164); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-28 (study day 78); relationship: not assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 37); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.